A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. (Q37315930)

19 August 2017

1 reference

title

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. (English)

1 reference

19 August 2017

1 reference

United States of America

1 reference

3

Lauri E Markowitz

1 reference

19 August 2017

Eileen F Dunne

1

1 reference

PubMed ID

18980283

19 August 2017

S Deblina Datta

series ordinal

2

1 reference

PubMed ID

18980283

19 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

113

1 reference

19 August 2017

10 Suppl

1 reference

19 August 2017

2995-3003

1 reference

Concordance of human papillomavirus in the cervix and urine among inner city adolescents

19 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

Prevention of human papillomavirus infection: provisional recommendations for immunization of girls and women with quadrivalent human papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

The Vaccine Safety Datalink project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

The global health burden of infection-associated cancers in the year 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Chapter 2: The burden of HPV-related cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Prevalence of HPV infection among females in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Detection of genital human papillomavirus and associated cytological abnormalities among college women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Prevalence of HPV infection among men: A systematic review of the literature.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Human papillomavirus prevalence and type distribution in male anogenital sites and semen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

A 2‐Year Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low‐Grade Squamous Intraepithelial Lesion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23763

7 January 2021

Identifiers

DOI

10.1002/CNCR.23763

1 reference

19 August 2017

1 reference

PubMed ID

18980283